| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Amino acid–anticodon binding specificity: rationale for a new class of therapeutic agent
|
Melzer, Marvin S.
|
|
2012
|
|
7-8 |
p. 291-295
5 p.
|
artikel
|
| 2 |
Application of technologies and parallel chemistry for the generation of actives against biological targets
|
Edwards, P.
|
|
2008
|
|
7-8 |
p. 368-369
2 p.
|
artikel
|
| 3 |
Assessing drug-likeness – what are we missing?
|
Vistoli, Giulio
|
|
2008
|
|
7-8 |
p. 285-294
10 p.
|
artikel
|
| 4 |
Biomarkers for simplifying HTS 3D cell culture platforms for drug discovery: the case for cytokines
|
Lai, Yinzhi
|
|
2011
|
|
7-8 |
p. 293-297
5 p.
|
artikel
|
| 5 |
Brain tumor immunotherapy: seeing the brain in the body
|
Lampson, Lois A.
|
|
2013
|
|
7-8 |
p. 399-406
8 p.
|
artikel
|
| 6 |
Buccal iontophoresis: an opportunity for drug delivery and metabolite monitoring
|
Ciach, Tomasz
|
|
2011
|
|
7-8 |
p. 361-366
6 p.
|
artikel
|
| 7 |
Can biochemistry drive drug discovery beyond simple potency measurements?
|
Chène, Patrick
|
|
2012
|
|
7-8 |
p. 388-395
8 p.
|
artikel
|
| 8 |
Can we discover pharmacological promiscuity early in the drug discovery process?
|
Peters, Jens-Uwe
|
|
2012
|
|
7-8 |
p. 325-335
11 p.
|
artikel
|
| 9 |
Capillary electrophoresis and small molecule drug discovery: a perfect match?
|
Espada, Alfonso
|
|
2012
|
|
7-8 |
p. 396-404
9 p.
|
artikel
|
| 10 |
Case study: adapting in vitro blood–brain barrier models for use in early-stage drug discovery
|
Vandenhaute, Elodie
|
|
2012
|
|
7-8 |
p. 285-290
6 p.
|
artikel
|
| 11 |
Cell-surface and cytokine biomarkers in autoimmune and inflammatory diseases
|
O’Hara Jr, Richard M.
|
|
2006
|
|
7-8 |
p. 342-347
6 p.
|
artikel
|
| 12 |
αC helix displacement as a general approach for allosteric modulation of protein kinases
|
Palmieri, Lorenzo
|
|
2013
|
|
7-8 |
p. 407-414
8 p.
|
artikel
|
| 13 |
Chronic autoimmune-mediated inflammation: a senescent immune response to injury
|
’t Hart, Bert A.
|
|
2013
|
|
7-8 |
p. 372-379
8 p.
|
artikel
|
| 14 |
Classification of scaffold-hopping approaches
|
Sun, Hongmao
|
|
2012
|
|
7-8 |
p. 310-324
15 p.
|
artikel
|
| 15 |
Clinical and economic impact of the nonresponder phenomenon – implications for systems based discovery
|
Jackson, David B.
|
|
2009
|
|
7-8 |
p. 380-385
6 p.
|
artikel
|
| 16 |
Cochlear implantation: an opportunity for drug development
|
Staecker, Hinrich
|
|
2010
|
|
7-8 |
p. 314-321
8 p.
|
artikel
|
| 17 |
Computational models for predicting substrates or inhibitors of P-glycoprotein
|
Chen, Lei
|
|
2012
|
|
7-8 |
p. 343-351
9 p.
|
artikel
|
| 18 |
Computational models for prediction of interactions with ABC-transporters
|
Ecker, Gerhard F.
|
|
2008
|
|
7-8 |
p. 311-317
7 p.
|
artikel
|
| 19 |
Computational systems biology in drug discovery and development: methods and applications
|
Materi, Wayne
|
|
2007
|
|
7-8 |
p. 295-303
9 p.
|
artikel
|
| 20 |
Computational toxicology in drug development
|
Muster, Wolfgang
|
|
2008
|
|
7-8 |
p. 303-310
8 p.
|
artikel
|
| 21 |
Contents
|
|
|
2009
|
|
7-8 |
p. i-
1 p.
|
artikel
|
| 22 |
Contents
|
|
|
2009
|
|
7-8 |
p. iii-
1 p.
|
artikel
|
| 23 |
Contents
|
|
|
2008
|
|
7-8 |
p. i-
1 p.
|
artikel
|
| 24 |
Contents
|
|
|
2013
|
|
7-8 |
p. i-
1 p.
|
artikel
|
| 25 |
Contents
|
|
|
2013
|
|
7-8 |
p. iii-
1 p.
|
artikel
|
| 26 |
Contents page 2
|
|
|
2010
|
|
7-8 |
p. iii-
1 p.
|
artikel
|
| 27 |
Contents page 1
|
|
|
2010
|
|
7-8 |
p. i-
1 p.
|
artikel
|
| 28 |
Contents page 1
|
|
|
2011
|
|
7-8 |
p. i-
1 p.
|
artikel
|
| 29 |
Contents page 2
|
|
|
2011
|
|
7-8 |
p. iii-
1 p.
|
artikel
|
| 30 |
Contents page 2
|
|
|
2012
|
|
7-8 |
p. iii-
1 p.
|
artikel
|
| 31 |
Contents page 1
|
|
|
2012
|
|
7-8 |
p. i-
1 p.
|
artikel
|
| 32 |
Critical review of the role of HTS in drug discovery
|
Macarron, Ricardo
|
|
2006
|
|
7-8 |
p. 277-279
3 p.
|
artikel
|
| 33 |
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention
|
Broussalis, Erasmia
|
|
2012
|
|
7-8 |
p. 296-309
14 p.
|
artikel
|
| 34 |
Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration
|
Yang, Da-Qing
|
|
2011
|
|
7-8 |
p. 332-338
7 p.
|
artikel
|
| 35 |
DDT April Diary
|
|
|
2007
|
|
7-8 |
p. 347-
1 p.
|
artikel
|
| 36 |
Decision support methods for the detection of adverse events in post-marketing data
|
Hauben, M.
|
|
2009
|
|
7-8 |
p. 343-357
15 p.
|
artikel
|
| 37 |
Delivery of anti-angiogenic molecular therapies for retinal disease
|
Anderson, Owen A.
|
|
2010
|
|
7-8 |
p. 272-282
11 p.
|
artikel
|
| 38 |
Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus
|
Zoller, Frank A.
|
|
2013
|
|
7-8 |
p. 318-322
5 p.
|
artikel
|
| 39 |
Determinants for successful marketing authorisation of orphan medicinal products in the EU
|
Putzeist, Michelle
|
|
2012
|
|
7-8 |
p. 352-358
7 p.
|
artikel
|
| 40 |
Diary
|
|
|
2006
|
|
7-8 |
p. 372-
1 p.
|
artikel
|
| 41 |
Diverse roles of the scaffolding protein RanBPM
|
Suresh, Bharathi
|
|
2012
|
|
7-8 |
p. 379-387
9 p.
|
artikel
|
| 42 |
Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development
|
Peck, Richard W.
|
|
2007
|
|
7-8 |
p. 289-294
6 p.
|
artikel
|
| 43 |
Drug screening for hearing loss: Using the zebrafish lateral line to screen for drugs that prevent and cause hearing loss
|
Ou, Henry C.
|
|
2010
|
|
7-8 |
p. 265-271
7 p.
|
artikel
|
| 44 |
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations
|
Gabrielsson, Johan
|
|
2009
|
|
7-8 |
p. 358-372
15 p.
|
artikel
|
| 45 |
Editorial Board
|
|
|
2008
|
|
7-8 |
p. iii-
1 p.
|
artikel
|
| 46 |
Fragment screening to predict druggability (ligandability) and lead discovery success
|
Edfeldt, Fredrik N.B.
|
|
2011
|
|
7-8 |
p. 284-287
4 p.
|
artikel
|
| 47 |
Getting the most out of your IP – patent management along its life cycle
|
Bader, Martin A.
|
|
2012
|
|
7-8 |
p. 281-284
4 p.
|
artikel
|
| 48 |
Graham Dixon talks about his career, his involvement with the Society for Chemical Industries and the development of SCIpharm2006
|
Carney, Steve
|
|
2006
|
|
7-8 |
p. 280-282
3 p.
|
artikel
|
| 49 |
Grants4Targets – an innovative approach to translate ideas from basic research into novel drugs
|
Lessl, Monika
|
|
2011
|
|
7-8 |
p. 288-292
5 p.
|
artikel
|
| 50 |
Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies
|
Dixit, Rakesh
|
|
2007
|
|
7-8 |
p. 336-342
7 p.
|
artikel
|
| 51 |
Healthy skepticism: assessing realistic model performance
|
Brown, Scott P.
|
|
2009
|
|
7-8 |
p. 420-427
8 p.
|
artikel
|
| 52 |
Hearing loss and tinnitus – the hidden healthcare time bomb
|
Goldman, Denise R.
|
|
2010
|
|
7-8 |
p. 253-255
3 p.
|
artikel
|
| 53 |
How to compute which genes control drug resistance dynamics
|
Guo, Yunqian
|
|
2011
|
|
7-8 |
p. 339-344
6 p.
|
artikel
|
| 54 |
Human Microbiome Project—paving the way to a better understanding of ourselves and our microbes
|
Hsiao, William W.L.
|
|
2009
|
|
7-8 |
p. 331-333
3 p.
|
artikel
|
| 55 |
If you want to shoot for the moon, you gotta have the right stuff
|
Bradley, Mary
|
|
2012
|
|
7-8 |
p. 279-280
2 p.
|
artikel
|
| 56 |
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
|
Barbosa, Maria D.F.S.
|
|
2011
|
|
7-8 |
p. 345-353
9 p.
|
artikel
|
| 57 |
Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions
|
Matter, Alex
|
|
2008
|
|
7-8 |
p. 347-352
6 p.
|
artikel
|
| 58 |
Inhibitors of the Hdm2:p53 complex as antitumour agents
|
Westwell, Andrew D.
|
|
2006
|
|
7-8 |
p. 371-
1 p.
|
artikel
|
| 59 |
Injectable implants for the sustained release of protein and peptide drugs
|
Agarwal, Priyanka
|
|
2013
|
|
7-8 |
p. 337-349
13 p.
|
artikel
|
| 60 |
Insights into liaison between antiepileptic drugs and bone
|
Khanna, Suruchi
|
|
2009
|
|
7-8 |
p. 428-435
8 p.
|
artikel
|
| 61 |
In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: beyond the reduction of animal model use
|
Huynh, Lucie
|
|
2009
|
|
7-8 |
p. 401-405
5 p.
|
artikel
|
| 62 |
In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part II: the body in a Hilbertian space
|
Jacob, Alexandre
|
|
2009
|
|
7-8 |
p. 406-412
7 p.
|
artikel
|
| 63 |
In silico repositioning of approved drugs for rare and neglected diseases
|
Ekins, Sean
|
|
2011
|
|
7-8 |
p. 298-310
13 p.
|
artikel
|
| 64 |
Integrating molecular design resources within modern drug discovery research: the Roche experience
|
Stahl, Martin
|
|
2006
|
|
7-8 |
p. 326-333
8 p.
|
artikel
|
| 65 |
Ischemic acute tubular necrosis models and drug discovery: a focus on cellular inflammation
|
Ikeda, Masahiro
|
|
2006
|
|
7-8 |
p. 364-370
7 p.
|
artikel
|
| 66 |
Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?
|
Costantino, Luca
|
|
2012
|
|
7-8 |
p. 367-378
12 p.
|
artikel
|
| 67 |
Kinases as drug targets in the treatment of bipolar disorder
|
Catapano, Lisa A.
|
|
2008
|
|
7-8 |
p. 295-302
8 p.
|
artikel
|
| 68 |
Managing protein flexibility in docking and its applications
|
B-Rao, Chandrika
|
|
2009
|
|
7-8 |
p. 394-400
7 p.
|
artikel
|
| 69 |
Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents
|
Holenz, Jörg
|
|
2006
|
|
7-8 |
p. 283-299
17 p.
|
artikel
|
| 70 |
Modulating receptor function through RAMPs: can they represent drug targets in themselves?
|
Sexton, Patrick M.
|
|
2009
|
|
7-8 |
p. 413-419
7 p.
|
artikel
|
| 71 |
Molecular perspectives on the non-responder phenomenon
|
Jackson, David B.
|
|
2009
|
|
7-8 |
p. 373-379
7 p.
|
artikel
|
| 72 |
Multiple active receptor conformation, agonist efficacy and maximum effect of the system: the conformation-based operational model of agonism
|
Roche, David
|
|
2013
|
|
7-8 |
p. 365-371
7 p.
|
artikel
|
| 73 |
Nanonization strategies for poorly water-soluble drugs
|
Chen, Huabing
|
|
2011
|
|
7-8 |
p. 354-360
7 p.
|
artikel
|
| 74 |
New agents for the treatment of leukemia: discovery of DMAPT (LC-1)
|
Peese, Kevin
|
|
2010
|
|
7-8 |
p. 322-
1 p.
|
artikel
|
| 75 |
New therapies to treat sight loss in an ageing population
|
Conroy, Dolores M.
|
|
2010
|
|
7-8 |
p. 256-259
4 p.
|
artikel
|
| 76 |
Novel antitussive strategies
|
Morjaria, Jaymin B.
|
|
2013
|
|
7-8 |
p. 380-388
9 p.
|
artikel
|
| 77 |
Omic profiling for drug safety assessment: current trends and public–private partnerships
|
Gallagher, William M.
|
|
2009
|
|
7-8 |
p. 337-342
6 p.
|
artikel
|
| 78 |
Open Innovation in Drug Discovery research comes of age
|
Judd, Duncan B.
|
|
2013
|
|
7-8 |
p. 315-317
3 p.
|
artikel
|
| 79 |
Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model
|
Hutchins, Steven
|
|
2011
|
|
7-8 |
p. 281-283
3 p.
|
artikel
|
| 80 |
Orphan enzymes could be an unexplored reservoir of new drug targets
|
Lespinet, Olivier
|
|
2006
|
|
7-8 |
p. 300-305
6 p.
|
artikel
|
| 81 |
Peptide aptamers as guides for small-molecule drug discovery
|
Baines, Ivan C.
|
|
2006
|
|
7-8 |
p. 334-341
8 p.
|
artikel
|
| 82 |
Pharmacological and therapeutic effects of A3 adenosine receptor agonists
|
Fishman, Pnina
|
|
2012
|
|
7-8 |
p. 359-366
8 p.
|
artikel
|
| 83 |
Pharmacological approaches to the treatment of tinnitus
|
Elgoyhen, Ana B.
|
|
2010
|
|
7-8 |
p. 300-305
6 p.
|
artikel
|
| 84 |
Pharmacological treatments of fibromyalgia: Do complex conditions need complex therapies?
|
Lawson, Kim
|
|
2008
|
|
7-8 |
p. 333-340
8 p.
|
artikel
|
| 85 |
Physiological, pathological and potential therapeutic roles of ghrelin
|
Leite-Moreira, Adelino F.
|
|
2007
|
|
7-8 |
p. 276-288
13 p.
|
artikel
|
| 86 |
PK/PD modelling and simulations: utility in drug development
|
Rajman, Iris
|
|
2008
|
|
7-8 |
p. 341-346
6 p.
|
artikel
|
| 87 |
Preclinical models of arthritic disease in non-human primates
|
Vierboom, Michel P.M.
|
|
2007
|
|
7-8 |
p. 327-335
9 p.
|
artikel
|
| 88 |
Protein structure prediction and model quality assessment
|
Kryshtafovych, Andriy
|
|
2009
|
|
7-8 |
p. 386-393
8 p.
|
artikel
|
| 89 |
Quinolines: a new hope against inflammation
|
Mukherjee, Soumita
|
|
2013
|
|
7-8 |
p. 389-398
10 p.
|
artikel
|
| 90 |
Raju Kucherlapati talks about personalised medicine: breathing new life into old drugs
|
Carney, Steve
|
|
2007
|
|
7-8 |
p. 272-275
4 p.
|
artikel
|
| 91 |
Research & market strategy: how choice of drug discovery approach can affect market position
|
Sams-Dodd, Frank
|
|
2007
|
|
7-8 |
p. 314-318
5 p.
|
artikel
|
| 92 |
Science aside: the trajectory of embryonic stem cell research in the USA
|
Schlaeger, Thorsten M.
|
|
2007
|
|
7-8 |
p. 269-271
3 p.
|
artikel
|
| 93 |
Screening isolates from antibody phage-display libraries
|
Buckler, David R.
|
|
2008
|
|
7-8 |
p. 318-324
7 p.
|
artikel
|
| 94 |
Serotoninergic mechanisms in the treatment of obsessive–compulsive disorder
|
Goddard, Andrew W.
|
|
2008
|
|
7-8 |
p. 325-332
8 p.
|
artikel
|
| 95 |
Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells
|
Byrne, Barry
|
|
2007
|
|
7-8 |
p. 319-326
8 p.
|
artikel
|
| 96 |
Similarity in drugs: reflections on analogue design
|
Wermuth, Camille G.
|
|
2006
|
|
7-8 |
p. 348-354
7 p.
|
artikel
|
| 97 |
Small and colorful stones make beautiful mosaics: fragment-based chemogenomics
|
de Graaf, Chris
|
|
2013
|
|
7-8 |
p. 323-330
8 p.
|
artikel
|
| 98 |
Snapshot PK: a rapid rodent in vivo preclinical screening approach
|
Liu, Bo
|
|
2008
|
|
7-8 |
p. 360-367
8 p.
|
artikel
|
| 99 |
Status of text-mining techniques applied to biomedical text
|
Erhardt, Ramón A-A.
|
|
2006
|
|
7-8 |
p. 315-325
11 p.
|
artikel
|
| 100 |
Stem cells and cell lines from the human auditory organ: applications, hurdles and bottlenecks in the development of regenerative therapies for deafness
|
Rivolta, Marcelo N.
|
|
2010
|
|
7-8 |
p. 283-286
4 p.
|
artikel
|
| 101 |
Stem cell technology for drug discovery and development
|
Hook, Lilian A.
|
|
2012
|
|
7-8 |
p. 336-342
7 p.
|
artikel
|
| 102 |
Stem cell therapies for ocular surface disease
|
Ahmad, Sajjad
|
|
2010
|
|
7-8 |
p. 306-313
8 p.
|
artikel
|
| 103 |
Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies
|
Dahlmann-Noor, A.H.
|
|
2010
|
|
7-8 |
p. 287-299
13 p.
|
artikel
|
| 104 |
Strategies to optimize the validity of disease models in the drug discovery process
|
Sams-Dodd, Frank
|
|
2006
|
|
7-8 |
p. 355-363
9 p.
|
artikel
|
| 105 |
Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness
|
Han, Lian Yi
|
|
2007
|
|
7-8 |
p. 304-313
10 p.
|
artikel
|
| 106 |
Supramolecular devices to improve the treatment of brain diseases
|
Paolino, Donatella
|
|
2011
|
|
7-8 |
p. 311-324
14 p.
|
artikel
|
| 107 |
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
|
Zhang, Yan-Jie
|
|
2011
|
|
7-8 |
p. 325-331
7 p.
|
artikel
|
| 108 |
Tetramic and tetronic acids as β-secretase inhibitors
|
Edwards, Paul
|
|
2007
|
|
7-8 |
p. 345-346
2 p.
|
artikel
|
| 109 |
The conductor and his orchestra
|
Lewi, Paul J.
|
|
2008
|
|
7-8 |
p. 281-284
4 p.
|
artikel
|
| 110 |
The cryptome: a subset of the proteome, comprising cryptic peptides with distinct bioactivities
|
Autelitano, Dominic J.
|
|
2006
|
|
7-8 |
p. 306-314
9 p.
|
artikel
|
| 111 |
The future of discovery chemistry: quo vadis? Academic to industrial – the maturation of medicinal chemistry to chemical biology
|
Hoffmann, Torsten
|
|
2010
|
|
7-8 |
p. 260-264
5 p.
|
artikel
|
| 112 |
The genetics of a pharma merger
|
Sanseau, Philippe
|
|
2009
|
|
7-8 |
p. 334-336
3 p.
|
artikel
|
| 113 |
The holistic integration of virtual screening in drug discovery
|
Tanrikulu, Yusuf
|
|
2013
|
|
7-8 |
p. 358-364
7 p.
|
artikel
|
| 114 |
The piperazine core of tricyclic farnesyltransferase inhibitors
|
Edwards, Paul
|
|
2007
|
|
7-8 |
p. 343-344
2 p.
|
artikel
|
| 115 |
The role of users in innovation in the pharmaceutical industry
|
Smits, Ruud E.H.M.
|
|
2008
|
|
7-8 |
p. 353-359
7 p.
|
artikel
|
| 116 |
The use of combinatorial chemistry libraries for the discovery of biologically active substances
|
Edwards, Paul
|
|
2009
|
|
7-8 |
p. 436-437
2 p.
|
artikel
|
| 117 |
Torching the Haystack: modelling fast-fail strategies in drug development
|
Lendrem, Dennis W.
|
|
2013
|
|
7-8 |
p. 331-336
6 p.
|
artikel
|
| 118 |
Transcriptional data: a new gateway to drug repositioning?
|
Iorio, Francesco
|
|
2013
|
|
7-8 |
p. 350-357
8 p.
|
artikel
|
| 119 |
Whither antibacterial drug discovery?
|
Projan, Steven J.
|
|
2008
|
|
7-8 |
p. 279-280
2 p.
|
artikel
|
Tijdschrift beschrijving